Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Wave 80 Biosciences Inc
Profile last edited on: 12/31/20      CAGE: 3FJ37      UEI: XDG6MCTKJEW7

Business Identifier: Molecular diagnostics instruments and consumables, focusing on HIV.
Year Founded
2003
First Award
2003
Latest Award
2015
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2325 Third Street Suite 215
San Francisco, CA 94107
   (415) 513-0683
   info@wave80.com
   www.wave80.com
Location: Single
Congr. District: 12
County: San Francisco

Public Profile

Wave 80 Biosciences, Inc. develops molecular diagnostics instruments and consumables for hepatitis C, hepatitis B, HIV/AIDS, infectious diseases, cancer, autoimmune diseases, and other human health conditions. The firm's lead product is EOSCAPE-HIV, which measures the quantity of HIV RNA in peripheral blood. EOSCAPE-HIV is a cartridge-format in vitro nucleic acid assay.

Extent of SBIR involvement

User Avatar
Phase I Awards
12
Phase II Awards
6
Conversion Rate
50.00%
Phase I Dollars
$2,968,157
Phase II Dollars
$3,923,263
Total Awarded
$6,891,420

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2015 2 NIH $600,000
Project Title: Rapid No-Spin Chlamydia Rna Extraction Via Filtering; Lysis and Monolith Binding
2014 1 NIH $207,164
Project Title: Automated POC Extraction of Sputum-Borne Bacterial Nucleic Acids in the Clinic
2014 2 NIH $372,417
Project Title: A Point of Care, Nucleic Acid Test for Chlamydia to Ensure Prompt Treatment of He
2013 1 NIH $219,779
Project Title: Wave 80 Biosciences, Inc.
2013 1 NIH $161,087
Project Title: Chelated Lanthanide Emission Fingerprinting For Multiplexed Homogeneous Nat

Key People / Management

  Daniel J Laser -- CEO and President

  Andrew M Arsham -- Vice President, Assay Research

  Amy Droitcour -- Vice President, Engineering

  Richard Goozh -- CFO & SVP, Finance and Administration

  Laura Mazzola -- Senior Vice President, Global Initiatives

Company News

Sep 26 2014
USSOCOM SBIR Successful Technology Pursuit - SOF MicroLab